Adaptimmune has bagged two milestones from GlaxoSmithKline. The checks landed in Adaptimmune's bank account after it tripled the size of a Phase I/II synovial sarcoma trial of its NY-ESO-1-targeting T-cell receptor (TCR) therapy on the strength of data from the initial cohort.
Alexion Pharmaceuticals is no longer a one-product company, winning tandem European approvals for two rare disease drugs it hopes will mimic the success of Soliris, the world's most expensive treatment.
Welcome to the latest edition of our weekly EuroBiotech Report. Kelly Martin is back in the hotseat at a biopharma business. Malin, the life science fund Martin helped to set up, gave the former Elan...
A few months ago, the European Medicines Agency followed through on a threatened continental marketing halt affecting about 700 drugs in Indian CRO GVK Biosciences' generic lineup due to allegations of manipulated trial results. Now, Germany's regulators have suspended another 54 drugs tested by GVK in accordance with the EMA's recommendations.
Lundbeck has initiated a rejig of its pipeline, taking an ax to undisclosed early-stage assets in order to funnel cash into what it sees as its most promising candidates. The schizophrenia drug Lu AF35700 is among the beneficiaries of the reshuffle, with Lundbeck using its reorganized balance sheet to advance the therapy through development unpartnered.
Digital health startups attracted $4 billion in venture capital in the U.S. last year, compared with about $110 million in Europe.
As med tech companies target innovative devices that can rapidly diagnose conditions such as sepsis, a team of researchers in Germany and Ireland are developing a device that could slash testing times for urinary tract infections.
U.S. CRO Accelovance is blueprinting a new site in Wales, planning to add 70 positions as it builds out its European ranks.
In this week's EuroBiotech Report, Bristol-Myers Squibb handed over $15 million (€13.5 million) to add three targets to its collaboration with uniQure and a further $38 million to up its stake in its partner to just shy of 10%. UniQure is in line to pocket more money as the number of targets put forward by Bristol-Myers increases beyond the four selected to date. And more.
Wilex has become one of the early losers of the immuno-oncology gold rush. The blow was dealt by Roche, which has axed its alliance with Wilex subsidiary Heidelberg Pharma as part of its retreat from areas of cancer R&D beyond immuno-oncology.